Wall Road is experiencing a interval of uncertainty, buying and selling totally on the fixed updates and headlines about Iran and the Strait of Hormuz. The bulls are exhibiting they’re prepared and prepared to carry their floor primarily based on the prospects of de-escalation within the rapid future.
If the Center East battle is resolved sooner quite than later, the market seems to be in a superb place for the reason that earnings outlook retains getting higher. That stated, buyers seeking to purchase shares ought to take into account corporations which have already confirmed they can keep far above the Iran-based promoting.
The momentum shares this display places in your radar haven’t solely climbed to commerce close to their highs amid March market turmoil, however they’ve additionally skilled robust upward earnings revisions that earn them Zacks Rank #1 (Sturdy Buys) proper now.
Let’s dive into how buyers can discover the perfect “Sturdy Purchase” momentum shares so as to add to their portfolios heading into April and all through 2026.
The best way to Discover the Prime Momentum Shares to Purchase
The display we’re trying into in the present day comes loaded with the Analysis Wizard. The display helps buyers dig by way of all the Zacks Rank #1 (Sturdy Purchase) shares, of which there are over 200 at any given time, to seek out among the prime momentum names.
The display narrows down the record of Zacks Rank #1 (Sturdy Purchase) stocksto these with upward worth momentum which might be additionally buying and selling inside 20% of their 52-week highs. The display then makes use of the PEG ratio and the Worth to Gross sales ratio to assist be sure buyers are getting worth as nicely. The display then makes your life slightly simpler and narrows it down to only seven inventory picks.
The display fundamentals are listed under…
· Zacks Rank = #1 (Sturdy Purchase)
· Present Worth/52-week Excessive >= 0.8
· PEG Ratio: P/E F(1)/EPS Progress <= 1
· Worth/Gross sales <= 3
· Share Change Worth -12 Weeks = Prime # 7
This technique comes loaded with the Analysis Wizard and it’s known as bt_sow_momentum_method1 It may be discovered within the SoW (Display of the Week) folder.
The display is easy, but highly effective. Right here is one of the seven shares that made it by way of this week’s display…
Purchase Hovering Prime-Ranked Medical Inventory PAHC for Worth, Progress and Breakout Potential
Phibro Animal Well being Company PAHC is an animal well being and mineral diet firm that posted huge gross sales and earnings development final yr. The inventory has soared over 330% up to now two years, together with a 46% YTD cost to new all-time highs, which helped it escape above its earlier 2018 peaks.
Picture Supply: Zacks Funding Analysis
PAHC works with livestock producers, farmers, veterinarians, and shoppers. Phibro Animal Well being sells roughly 780 product traces in over 80 international locations to almost 4,000 clients to assist stop, management and deal with illnesses, and assist diet. Phibro Animal Well being’s choices are designed for meals and companion animals, together with poultry, swine, beef and dairy cattle, aquaculture, and canine.
The animal well being agency’s earnings estimates have surged since its final report, extending a powerful run of upward revisions. PAHC’s FY26 estimate has jumped 10% over the previous few months, with its FY27 outlook 12% greater, serving to it land its Zacks Rank #1 (Sturdy Purchase).
Phibro Animal Well being has grown its income steadily over the past decade, apart from a Covid-related dip, together with 27% gross sales enlargement in fiscal 2025 (ended on June 30).
Wanting forward, it’s projected to comply with that up with 15% income development in FY26 and 4% in FY27 to achieve $1.54 billion. It is usually anticipated to increase its adjusted earnings by 45% in FY26 and eight% subsequent yr, following 75% YoY enlargement in FY25.
Picture Supply: Zacks Funding Analysis
PAHC inventory held its floor at some key technical ranges. Plus, it trades at a 15% low cost to its Medical sector, at its personal 10-year median, and a 38% low cost to its highs at 16.7X ahead 12-month earnings.
That’s removed from a lofty valuation and showcases that PAHC inventory may have loads extra room to run given its spectacular development outlook.
Get the remainder of the shares on this record and begin on the lookout for the latest corporations that match these standards. It is easy to do. And it may enable you to discover your subsequent massive winner. Begin screening for these corporations in the present day with a free trial to the Analysis Wizard. You are able to do it.
Click on right here to join a free trial to the Analysis Wizard in the present day.
Need extra articles from this writer? Scroll as much as the highest of this text and click on the FOLLOW AUTHOR button to get an electronic mail every time a brand new article is printed.
Disclosure: Officers, administrators and/or workers of Zacks Funding Analysis might personal or have bought brief securities and/or maintain lengthy and/or brief positions in choices which might be talked about on this materials. An affiliated funding advisory agency might personal or have bought brief securities and/or maintain lengthy and/or brief positions in choices which might be talked about on this materials.
Disclosure: Efficiency data for Zacks’ portfolios and methods can be found at: www.zacks.com/performance_disclosure
See Right now’s Picks from Zacks’ Prime Screens – Free
You are invited to entry our assortment {of professional} inventory screens free of charge contained in the Analysis Wizard.
These screens have crushed the market since 2000. For instance, Small-Cap Progress averages +42.9% annual features, Filtered Zacks Rank5 returns +45.4%, and Massive Cash Zacks generates +51.8%.
Strive these screens for your self with a FREE Analysis Wizard trial. Or create your individual methods to suit your distinctive buying and selling fashion. No bank card wanted, no price or obligation.
Strive it for two weeks free >>
Phibro Animal Well being Company (PAHC) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
